Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16893631 | 1.00 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL22540834 | 0.92 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL16893900 | 0.92 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL20921387 | 0.92 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL16893903 | 0.92 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL16893663 | 0.90 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL16893661 | 0.90 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL16893635 | 0.88 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL16893873 | 0.88 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL16893815 | 0.87 | PTGS2 (0.69) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| WO-2015109014-A1 | NO-RELEASING NONOATE(OXYGEN-BOUND)CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015109011-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | PTGS2 1336/4885PTGS1 901/4885 |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.